As a Professor in the Department of Neurology and Neurological Sciences at Stanford University Medical Center, Dr. Maarten Lansberg splits his time between clinical activities on the inpatient stroke service and in the ambulatory stroke clinic at Stanford Hospital, clinical stroke research, and education. Dr. Lansberg is a board-certified in Neurology and Vascular Neurology and has additional advanced training in MR imaging and Epidemiology. He is the director of Stanford’s Stroke Research Fellowship and co-director of Stanford’s Stroke Recovery Program. He is the principal investigator of the Stanford Regional Coordinating Center (RCC) for StrokeNet, an NINDS-funded network of 25 RCCs that is responsible for conducting all major NINDS-funded stroke trials.

Dr. Lansberg's research is focused on clinical trials for stroke, spanning the full breadth of stroke care, including acute intervention, prevention, and recovery trials. The majority of his NIH funded research has centered on the use of imaging biomarkers (specifically multimodal CT and MRI) to select patients for acute stroke interventions. Dr. Lansberg has served as the principal investigator of CRISP, a prospective cohort study to assess the utility of CT perfusion for patient selection and the Protocol Director of DEFUSE 3, a Phase 3 randomized controlled trial of endovascular therapy for acute stroke in the 6-16 hour time-window. DEFUSE 3 was conducted at 38 US sites and was the first trial to be funded and executed through StrokeNet, the NINDS clinical stroke trial network.